Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis

Slipicevic, Ana; Øy, Geir Frode; Rosnes, Anne Katrine Ree; Stakkestad, Øystein; Emilsen, Elisabeth; Engesæter, Birgit; Mælandsmo, Gunhild Mari; Flørenes, Viví Ann

doi:10.4161/cbt.22953

Cited by 20 publications

(18 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the combination of lovastatin and valproate was shown to reduce cell invasion of Acc-Meso-1, a human-derived MPM cell line [110]. HWANG et al [51] reported a synergistic effect of the combination of pemetrexed and simvastatin on apoptosis induction in MSTO-211 MPM cells by reactive oxygen [43] Inhibition of angiogenesis [44] Inhibition of invasion and metastasis [45] Induction of tumour differentiation [46] Reversion of multidrug resistance [47] Phase III: gastric cancer [48], colorectal cancer [49] Phase III: ongoing in SCLC [50] Preclinical [47,[51][52][53] Itraconazole Antifungal Induction of angiogenesis [54] Inhibition of hedgehog pathway [8] Phase II: NSCLC [55] Prostate cancer [56] Basal cell carcinoma [57] Preclinical [58] Arsenic trioxide Preclinical [52,85,88] Thalidomide Sickness in pregnant females (withdrawn) [29] Inhibition of angiogenesis [31] Inhibition of cell proliferation [32] Immunomodulatory function [33] FDA approved: multiple myeloma [34] Phase III [37] Anisomycin Antibiotic Induction of apoptosis [89] Preclinical [90] Preclinical [90]…”

Section: Statinsmentioning

confidence: 99%

“…Anisomycin is an antibiotic produced by Streptomyces griseolus, inhibiting protein synthesis [139]. It also acts as a protein translation inhibitor known to sensitise tumour cells to apoptosis induced by TNF-related apoptosis-inducing ligand (TRAIL) [89]. In H28 and REN MPM cell lines [90], anisomycin delivered at low subtoxic concentrations (25 ng·mL −1 ) was a potent sensitiser of apoptosis induced by TRAIL.…”

Section: Antibioticsmentioning

confidence: 99%

See 1 more Smart Citation

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

et al. 2018

View full text Add to dashboard Cite

Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have been approved in this disease. However, its incidence is expected to increase significantly, particularly in developing countries. Consequently, drug repurposing appears as an attractive strategy for drug development in MPM, since the known pharmacology and safety profile based on previous approvals of repurposed drugs allows for faster time-to-market for patients and lower treatment cost. This is critical in low- and middle-income countries where access to expensive drugs is limited. This review assesses the published preclinical and clinical data about drug repurposing in MPM.In this review, we identified 11 therapeutic classes that could be repositioned in mesothelioma. Most of these treatments have been evaluated , half have been evaluated in animal models of MPM and only three ( valproate, thalidomide and zoledronic acid) have been investigated in clinical trials, with limited benefits so far. Efforts could be coordinated to pursue further investigations and test promising drugs identified in preclinical experiments in appropriately designed clinical trials.

show abstract

Section: Statinsmentioning

confidence: 99%

Section: Antibioticsmentioning

confidence: 99%

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Moreover, it might be worthwhile to explore expression and function of TRAIL‐Rs in other diseases associated with activating KIT mutations, such as gastrointestinal stromal tumors, melanoma, seminoma, and acute myeloid leukemia. In melanoma, in vitro studies suggested anticancer activity of agonistic TRAIL‐R antibodies ; however, to our knowledge, the impact of KIT mutations on TRAIL sensitivity has not been investigated in this disease.…”

Section: Discussionmentioning

confidence: 99%

Activation of KIT modulates the function of tumor necrosis factor‐related apoptosis‐inducing ligand receptor (TRAIL‐R) in mast cells

Förster

Grotha

Seeger

et al. 2015

Allergy

View full text Add to dashboard Cite

show abstract

“…Combinational therapy represents a potential strategy for treating TRAIL resistant cancers. In line with this, Lexatumumab has shown promising results in preclinical studies of melanoma, in particular in combination with other agents such as Dacarbazine[149] and Anisomycin[150]. Treatment with Lexatumumab is generally well tolerated as assessed in a Clinical phase I trial of pediatric patients with solid tumours[151].…”

mentioning

confidence: 87%

Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma

Magnussen

Rosnes

Shahzidi

et al. 2012

Biochemical and Biophysical Research Communications

Self Cite

View full text Add to dashboard Cite

Background: Malignant melanoma has an increasing incidence rate and the metastatic disease is notoriously resistant to standard chemotherapy. Loss of cell cycle checkpoints is frequently found in many cancer types and makes the cells reliant on compensatory mechanisms to control progression. This feature may be exploited in therapy, and kinases involved in checkpoint regulation, such as Wee1 and Chk1/2, have thus become attractive therapeutic targets. Methods: In the present study we combined a Wee1 inhibitor (MK1775) with Chk1/2 inhibitor (AZD7762) in malignant melanoma cell lines grown in vitro (2D and 3D cultures) and in xenografts models. Results: Our in vitro studies showed that combined inhibition of Wee1 and Chk1/2 synergistically decreased viability and increased apoptosis (cleavage of caspase 3 and PARP), which may be explained by accumulation of DNA-damage (increased expression of γ-H2A.X)-and premature mitosis of S-phase cells. Compared to either inhibitor used as single agents, combined treatment reduced spheroid growth and led to greater tumour growth inhibition in melanoma xenografts. Conclusions: These data provide a rationale for further evaluation of the combination of Wee1 and Chk1/2 inhibitors in malignant melanoma.

show abstract

Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis

Cited by 20 publications

References 38 publications

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

Activation of KIT modulates the function of tumor necrosis factor‐related apoptosis‐inducing ligand receptor (TRAIL‐R) in mast cells

Synthetic retinoid CD437 induces apoptosis and acts synergistically with TRAIL receptor-2 agonist in malignant melanoma

Contact Info

Product

Resources

About